Deutsche Bank has reiterated its Hold rating and 1,900p price target on GSK (LSE:GSK), with the stock last closing at 1,924.50p, implying modest downside to the analyst's target.
Analyst Emmanuel Papadakis published the bank's weekly IQVIA prescription tracker, covering data to 12 June, and found that GSK's key assets are broadly maintaining trends established in prior weeks, with no material shifts in direction.
On a four-week rolling basis, HIV total prescriptions rose 3%, new prescriptions were flat and new-to-brand scripts increased 12%; extrapolating those trends into full-year 2026, Papadakis sees single-digit upside versus consensus for Seretide and Nucala, single-digit downside for Dovato and Cabenuva, double-digit upside for Shingrix and Apretude, and double-digit downside for Trelegy and Triumeq.
The mixed product-level picture supports Deutsche Bank's cautious near-term stance, with weekly prescription releases serving as the key proof point the analyst will watch for evidence that script trends translate into full-year sales versus consensus expectations.
